CEBPA and acute myeloid leukemia: Specifically, point mutations were widely observed in AML patients,10 with 90% of them containing N‐terminal frame‐shift mutations.11 Such nonsense mutations would prevent correct translation of the full length C/EBPα peptide, but the expression of a truncated isoform (C/EBPα‐p30) is not affected.